Please assess the completion status of the following clinical trial:

Trial Title: Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients previously enrolled in C87059 (COSPAR I, NCT00349752)~Exclusion Criteria:~* Subject withdrawn or discontinued from C87059 (COSPAR I, NCT00349752) study under specific conditions~* Subject who received treatment other than study medication and other than medications permitted in C87059 (COSPAR I, NCT00349752)~* Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CDP870 400 mg (Type: EXPERIMENTAL): Certolizumab pegol (CDP870) 400 mg (2 injections of 1 mL) every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2

Based on this trial design, predict the completion outcome and termination type (if applicable).